Myelofibrosis Market Size and Trend Report 2023-2031: Projected $2.89 Billion Market by 2031 – MF Pipeline is Robust, with Plenty of Room for New Market Entrants – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Myelofibrosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Despite being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031 at a compound annual growth rate (CAGR) of 1.9%.

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for myelofibrosis (MF).

These sales forecasts leverage data on pharmaceutical sales and drug availability from the publisher’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for myelofibrosis (MF). These sales forecasts leverage data on pharmaceutical sales and drug availability from the publisher’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Despite being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, as shown in Figure 1, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales.

However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment paradigm.

Scope

• Overview of myelofibrosis, including epidemiology, symptoms, diagnosis, and disease management
• Annualized myelofibrosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the myelofibrosis therapeutics market
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for myelofibrosis treatment. The most promising candidates in Phase III and Phase IIb development are profiled
• Analysis of the current and future market competition in the global myelofibrosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Key Highlights

• Report deliverables include Excel-based forecast model
• Forecasts includes the 8MM
• Forecasts covers from 2021-2031
• Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031
• A moderate level of unmet need will remain for most myelofibrosis patient populations during the forecast period
• The late-stage pipeline in myelofibrosis is robust and is likely to provide significant clinical benefit to many myelofibrosis patient populations, with fierce competition expected

Several markets across the 8MM will experience growth driven by common drivers

• Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs
• Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents
• Increased utilization of novel combination regimens with premium-priced agents

Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries:

• Patent expiry of Jakafi/Jakavi
• Patent expiry of Vonjo (pacritinib)
• Patent expiry of Inrebic (fedratinib)

A selection of companies mentioned in this report includes

• Abbvie
• Acceleron Pharma
• Bristol Myers Squibb
• Constellation Pharmaceuticals
• CTI BioPharma
• Geron
• GSK
• Hangzhou Bangshun Pharmaceutical
• Huadong Medicine
• Impact Biomedicines
• Incyte
• Kartos Therapeutics
• Morphosys
• Novartis
• Sierra Oncology
• Suzhou Zelgen Pharmaceuticals

Key Topics Covered:

1 Myelofibrosis: Executive Summary

1.2 Novel JAK inhibitors and combination therapies will provide more holistic and robust treatment for myelofibrosis patients, including underserved patient populations

1.3 The level of unmet clinical need in myelofibrosis remains high during the forecast period, despite dramatic improvements by historical standards

1.4 The myelofibrosis pipeline is robust, with plenty of room for new market entrants

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.5 Epidemiological forecast of myelofibrosis (2021-31)

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL insights on disease management

5.2.1 Allogeneic hematopoietic cell transplant

5.2.2 Treatment for splenomegaly and constitutional symptoms

5.2.3 Treatment for anemia

5.2.4 US-specific KOL insights on disease management

5.2.5 EU-specific KOL Insights on Disease Management

5.2.6 China- and Japan-specific KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Controlling anemia in patients on ruxolitinib

7.3 Improving the Durability of Treatments

7.4 Drugs that target disease progression and improve survival

7.5 More patients are needed for clinical trials

7.6 More Therapies for Patients with Thrombocytopenia

8 R&D Strategies

8.1 Overview

8.1.1 Novel JAK inhibitors

8.1.2 Combination Therapies

8.1.3 Monotherapies

8.2 Clinical trials design

8.2.1 Primary and secondary endpoints of pivotal trials

8.2.2 Study inclusion and exclusion criteria

8.2.3 Future directions for myelofibrosis clinical trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.4 Japan

12.5 China

13 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5fohm3

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900